Porphyrins as Chelating Agents for Molecular Imaging in Nuclear Medicine
Porphyrin ligands, showing a significant affinity for cancer cells, also have the ability to chelate metallic radioisotopes to form potential diagnostic radiopharmaceuticals. They can be applied in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) to evaluate...
Main Authors: | Krystyna Pyrzynska, Krzysztof Kilian, Mateusz Pęgier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/10/3311 |
Similar Items
-
Increasing Reaction Rates of Water-Soluble Porphyrins for <sup>64</sup>Cu Radiopharmaceutical Labeling
by: Mateusz Pęgier, et al.
Published: (2023-03-01) -
Tumor Hypoxia Imaging Agents in Nuclear Medicine
by: Mahtab Mohammadpour, et al.
Published: (2017-01-01) -
Trends in the development of nuclear medicine in the Russian Federation for 2015–2020
by: L. A. Chipiga, et al.
Published: (2023-01-01) -
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
by: Shalini Sharma, et al.
Published: (2023-10-01) -
Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI
by: Maria-Argyro Karageorgou, et al.
Published: (2023-01-01)